Polycythemia Vera Presenting as Hemorrhagic Stroke
- PMID: 34295120
- PMCID: PMC8289499
- DOI: 10.1055/s-0041-1729478
Polycythemia Vera Presenting as Hemorrhagic Stroke
Abstract
Patients with polycythemia vera are at high risk for vaso-occlusive events including cerebral ischemia and hemorrhage. Cerebral ischemic events are due to increased blood viscosity and platelet activation within the central nervous system arterial vessels. We present a case of a 65-year-old woman who presented to the emergency department with seizures followed by left-sided weakness. Hematologic investigations revealed a hyperviscous state, and magnetic resonance imaging (MRI) was consistent with bilateral hemorrhagic infarction. Genetic studies were positive for polycythemia vera mutation. Symptoms improved with phlebotomy and antiplatelet agents. Through this case, we aim to highlight polycythemia vera as a cause of hemorrhagic stroke and the importance of blood counts in the routine evaluation of the same.
Keywords: hemorrhagic stroke; hypercoagulable state; polycythemia vera.
Association for Helping Neurosurgical Sick People. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.).
Conflict of interest statement
Conflict of interest None declared.
Figures





References
-
- Spivak J L. Polycythemia vera. Curr Treat Options Oncol. 2018;19(02):12. - PubMed
-
- Lim Y, Lee J O, Kim S H et al.Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thromb Res. 2015;135(05):846–851. - PubMed
-
- Marchioli R, Finazzi G, Specchia G et al.CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(01):22–33. - PubMed
-
- Gruppo Italiano Studio Policitemia . Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123(09):656–664. - PubMed
-
- Levine R L, Wadleigh M, Cools J et al.Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(04):387–397. - PubMed